Research recommendations coming out of this guidance How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested? How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from? How cost effective are cohort testing programmes: - as a stand-alone programme, or - as an extension of the NHS Health Check programme? How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment? What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care? What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C? What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C? What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment? Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment? How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?
How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?
How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?
How cost effective are cohort testing programmes: - as a stand-alone programme, or - as an extension of the NHS Health Check programme?
How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?
What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?
What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?
How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?
What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?
What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?
Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?
How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?